Prospeo
Hero Section BackgroundHero Section Background
Cybrexa Therapeutics

Cybrexa Therapeutics Email Formats

Biotechnology ResearchFlag of USNew Haven, Connecticut, United States11-20 Employees

Cybrexa Therapeutics Email Formats

Cybrexa Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@cybrexa.com), used 50% of the time.

FormatExamplePercentage
{first initial}.{last name}
j.doe@cybrexa.com
50%
{first name}.{last name}
john.doe@cybrexa.com
50%

Key Contacts at Cybrexa Therapeutics

Flag of US

Emily Reda

Sales Director

Flag of US

Waren Tolentino

Sales Director

Flag of US

Victor Facchini

Director, Fp&A

Company overview

Headquarters5 Science Park, New Haven, CT 06511, US
Phone number+18607991517
Website
NAICS541714
SIC873
Keywords
Oncology, Drug Development, Biotech, Phase I, DDR, Parp Inhibitor
Founded2017
Employees11-20
Socials

About Cybrexa Therapeutics

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent.pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces.pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc.alphalex™ represents the disruptive next generation in tumor targeting.Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology. For more information, visit www.cybrexa.com. Community Guidelines: https://bit.ly/3GI6AU0

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Director
Entry
C-Suite

Employees by Department

Cybrexa Therapeutics has 7 employees across 4 departments.

Departments

Number of employees

Funding Data

Explore Cybrexa Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date
Round
Amount
Link to Article
2021-04-105$25,000,000

Funding Insights

$25,000,000

Total funding amount

$25,000,000

Most recent funding amount

1

Number of funding rounds

Cybrexa Therapeutics Tech Stack

Discover the technologies and tools that power Cybrexa Therapeutics's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

reCAPTCHA

Security

jQuery Migrate

jQuery Migrate

JavaScript libraries

Cloudflare

Cloudflare

CDN

Twitter Emoji

Font scripts

jQuery

jQuery

JavaScript libraries

HTTP/3

HTTP/3

Miscellaneous

PHP

PHP

Programming languages

WordPress

WordPress

Blogs

Google Analytics

Google Analytics

Analytics

Bootstrap

Bootstrap

UI frameworks

Twenty Seventeen

Twenty Seventeen

WordPress themes

Yoast SEO

Yoast SEO

SEO

Frequently asked questions

Cybrexa Therapeutics is located in New Haven, Connecticut, US.
You can reach Cybrexa Therapeutics at +18607991517.
Cybrexa Therapeutics was founded in 2017, making it 9 years old. The company has established itself as a significant player in its industry over this time.
Cybrexa Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.
Cybrexa Therapeutics has raised a total of $25,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

4.8

40,000 users

top 50
high performer
most used
tier 1 accuracy

Build leads list with verified emails & mobiles